| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A century between pandemics and poisonings
|
Seftel, Matthew D
|
|
|
8 |
4 |
p. e251
|
artikel
|
| 2 |
Building an understanding of transgender care
|
The Lancet Haematology,
|
|
|
8 |
4 |
p. e241
|
artikel
|
| 3 |
CAR T-cell therapy roll-out in low-income and middle-income countries
|
Burki, Talha K
|
|
|
8 |
4 |
p. e252-e253
|
artikel
|
| 4 |
Correction to Lancet Haematol 2020; 7: e112–21
|
|
|
|
8 |
4 |
p. e249
|
artikel
|
| 5 |
Correction to Lancet Haematol 2021: 8: e254–66
|
|
|
|
8 |
4 |
p. e249
|
artikel
|
| 6 |
Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial
|
Sun, Lu
|
|
|
8 |
4 |
p. e289-e298
|
artikel
|
| 7 |
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)
|
Gillessen, Sarah
|
|
|
8 |
4 |
p. e278-e288
|
artikel
|
| 8 |
2 + 2 in the long term: informing a new standard of care in 2021 for early stage, unfavourable Hodgkin lymphoma
|
Doo, Nicole Wong
|
|
|
8 |
4 |
p. e243-e245
|
artikel
|
| 9 |
Late toxicities in non-Hodgkin lymphoma: extended follow-up matters
|
Thanarajasingam, Gita
|
|
|
8 |
4 |
p. e242-e243
|
artikel
|
| 10 |
Looking long-term: an unmet need in immune thrombocytopenia
|
Neunert, Cindy
|
|
|
8 |
4 |
p. e245-e246
|
artikel
|
| 11 |
Lucio Luzzatto: tackling blood disorders on multiple continents
|
Cavanaugh, Ray
|
|
|
8 |
4 |
p. e250
|
artikel
|
| 12 |
Model solutions for ethical allocation during cancer medicine shortages
|
Hantel, Andrew
|
|
|
8 |
4 |
p. e246-e248
|
artikel
|
| 13 |
Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review
|
Mohyuddin, Ghulam Rehman
|
|
|
8 |
4 |
p. e299-e304
|
artikel
|
| 14 |
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial
|
Frontzek, Fabian
|
|
|
8 |
4 |
p. e267-e277
|
artikel
|
| 15 |
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
|
Sharman, Jeff P
|
|
|
8 |
4 |
p. e254-e266
|
artikel
|
Tijdschrift beschrijving